BMC Cancer (Oct 2021)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers

  • Tatsunori Shimoi,
  • Jun Hashimoto,
  • Kazuki Sudo,
  • Akihiko Shimomura,
  • Emi Noguchi,
  • Chikako Shimizu,
  • Mayu Yunokawa,
  • Kan Yonemori,
  • Hiroshi Yoshida,
  • Masayuki Yoshida,
  • Tomoyasu Kato,
  • Takayuki Kinoshita,
  • Takahiro Fukuda,
  • Yasuhiro Fujiwara,
  • Kenji Tamura

DOI
https://doi.org/10.1186/s12885-021-08869-3
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background The V-Akt murine thymoma viral oncogene (AKT) 1 (E17K) is a subfamily of serine/threonine protein kinases that affects the survival, proliferation, and invasion of cancer cells. The clinicopathological features and frequencies in Asian populations with AKT1 mutations in breast and endometrial cancers are unclear. Hence, we aimed to determine the frequencies and relationships between clinicopathological features and AKT1 mutations in Asian women with cancer. Methods We extracted DNA from 311 and 143 samples derived from patients with breast and endometrial cancers to detect the AKT1 point mutation (hotspot), E17K. We examined correlations between clinicopathological features and AKT1 mutation status. Results The frequency of AKT1 mutations in breast cancer was 7.4%, and they were found more frequently in human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtypes, although this was not statistically significant (P = 0.08). The frequency of AKT1 mutations in endometrial cancer was 4.1%, and the mutations were histologically detected only in endometrioid types. However, AKT1 mutations did not correlate with relapse-free or overall survival of patients with breast or endometrial cancer. Conclusions AKT1 mutations are associated with HER2-negative subtype in breast cancer and in endometrial cancer with endometrioid histology. The frequencies of AKT1 mutations in breast and endometrial cancers were similar between Asian and other regional women. The frequency of mutations is too low in both tumor types to talk about predictive significance.

Keywords